Herz最新文献

筛选
英文 中文
Increased cardiovascular risk in patients with chronic kidney disease. 慢性肾病患者心血管风险增加。
IF 1.7 4区 医学
Herz Pub Date : 2024-03-01 Epub Date: 2024-02-28 DOI: 10.1007/s00059-024-05235-4
Sonja Vondenhoff, Stefan J Schunk, Heidi Noels
{"title":"Increased cardiovascular risk in patients with chronic kidney disease.","authors":"Sonja Vondenhoff, Stefan J Schunk, Heidi Noels","doi":"10.1007/s00059-024-05235-4","DOIUrl":"10.1007/s00059-024-05235-4","url":null,"abstract":"<p><p>Cardiovascular disease (CVD) is highly prevalent in patients suffering from chronic kidney disease (CKD). The risk of patients with CKD developing CVD is manifested already in the early stages of CKD development. The impact of declined kidney function on increased cardiovascular risk and the underlying mechanisms are complex and multifactorial. This review discusses the impact of (a) traditional cardiovascular risk factors such as smoking, dyslipidemia, diabetes, and hypertension as well as (b) CKD-specific pathophysiological and molecular mechanisms associated with an increased cardiovascular risk. The latter include uremic toxins, post-translational modifications and uremic lipids, innate immune cell activation and inflammation, oxidative stress, endothelial cell dysfunction, increased coagulation and altered platelet responses, vascular calcification, renin-angiotensin-aldosterone-system (RAAS) and sympathetic activation, as well as anemia. Unraveling the complex interplay of different risk factors, especially in the context of patient subcohorts, will help to find new therapeutic approaches in order to reduce the increased cardiovascular risk in this vulnerable patient cohort.</p>","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"95-104"},"PeriodicalIF":1.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10917854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139982807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Heart failure: update of the ESC 2023 guidelines]. [心力衰竭:ESC 2023指南的更新]。
IF 1.7 4区 医学
Herz Pub Date : 2024-02-01 Epub Date: 2023-11-14 DOI: 10.1007/s00059-023-05221-2
Johann Bauersachs, Samira Soltani
{"title":"[Heart failure: update of the ESC 2023 guidelines].","authors":"Johann Bauersachs, Samira Soltani","doi":"10.1007/s00059-023-05221-2","DOIUrl":"10.1007/s00059-023-05221-2","url":null,"abstract":"<p><p>The 2023 update of the European Society of Cardiology (ESC) guidelines recommends (class IA) the administration of sodium-glucose transporter 2 inhibitors (SGLT2i) also for patients with heart failure with preserved ejection fraction (HFpEF) and mildly reduced EF (HFmrEF). Thus, SGLT2i are the only medication that should be given to all heart failure patients for improvement of prognosis independent of left ventricular EF. The rapid administration of the fantastic four drugs and their prompt titration after a heart failure decompensation is now included in the guidelines with a class IB recommendation. For patients with reduced EF (HFrEF) or HFmrEF and iron deficiency there is now a class IIa recommendation for intravenous administration of ferric carboxymaltose or ferric derisomaltose.</p>","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"19-21"},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92153578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Update cardio-oncology : Immune checkpoint inhibitor therapy]. [更新心脏肿瘤学:免疫检查点抑制剂疗法]。
IF 1.7 4区 医学
Herz Pub Date : 2024-02-01 Epub Date: 2024-01-04 DOI: 10.1007/s00059-023-05228-9
Lars Michel, Tienush Rassaf
{"title":"[Update cardio-oncology : Immune checkpoint inhibitor therapy].","authors":"Lars Michel, Tienush Rassaf","doi":"10.1007/s00059-023-05228-9","DOIUrl":"10.1007/s00059-023-05228-9","url":null,"abstract":"<p><p>Cardiovascular diseases and cancer are the most common causes of death in Germany. Cancer treatment can lead to significant cardiovascular side effects and thus form a link between the two disease groups. The focus of cardio-oncology is on the best possible prevention, diagnostics and treatment of cardiovascular complications caused by cancer treatment. It is crucial for cardio-oncology to adapt to the continuous development of new forms of oncological treatment with previously unknown cardiovascular side effects. One such new form of treatment is immune checkpoint inhibitor (ICI) therapy, which is regarded as the most important oncological milestone of the last decade due to its excellent oncological efficacy; however, the growing use has revealed a high risk of diverse cardiovascular side effects with high morbidity and mortality, so that cardio-oncological care of affected patients is of particular importance. This review summarizes the current scientific and clinical state of the pathophysiology, incidence, diagnosis and treatment of cardiovascular side effects of ICI therapy.</p>","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"81-90"},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Ultrasound examination of the carotid artery for improved prediction of cardiovascular events and the effect of statin treatment in advanced atherosclerosis : An observational study]. [通过颈动脉超声波检查更好地预测心血管事件和他汀类药物治疗晚期动脉粥样硬化的效果:一项观察性研究]。
IF 1.7 4区 医学
Herz Pub Date : 2024-02-01 Epub Date: 2023-07-05 DOI: 10.1007/s00059-023-05197-z
Ansgar Adams, Waldemar Bojara, Michel Romanens
{"title":"[Ultrasound examination of the carotid artery for improved prediction of cardiovascular events and the effect of statin treatment in advanced atherosclerosis : An observational study].","authors":"Ansgar Adams, Waldemar Bojara, Michel Romanens","doi":"10.1007/s00059-023-05197-z","DOIUrl":"10.1007/s00059-023-05197-z","url":null,"abstract":"<p><strong>Background: </strong>Advanced atherosclerosis of the carotid artery is associated with a high risk of cardiovascular diseases. It was investigated whether ultrasound provides a better prediction of cardiovascular events compared to the prospective cardiovascular Münster study (PROCAM) score and whether treatment of subjects with advanced atherosclerosis with statins improves the prognosis.</p><p><strong>Method: </strong>Between 2009 and 2016 a total of 4482 subjects (41% women) aged 35-65 years with no signs of cardiovascular disease underwent carotid artery ultrasound examination. Total plaque area (TPA) and maximum plaque thickness were measured. The PROCAM score was used to determine the cardiovascular risk.</p><p><strong>Results: </strong>The median follow-up time was 77 months (6.4 years) for the men and 74 months (6.2 years) for the women. Events, such as myocardial infarction, ischemic stroke, coronary artery bypass grafting (CABG) and percutaneous transluminal coronary angioplasty (PTCA), occurred in 131 (3.4%) of the 3833 subjects with complete follow-up data. The prediction of cardiovascular events was better with ultrasound than with the PROCAM score. Ultrasound predicted 79.4% of 131 events and the PROCAM score predicted 22.9%. Treatment of subjects with advanced atherosclerosis (types III, IV b) with a statin significantly improved the prognosis. The event rate was 12.6% in men and women in the treated group vs. 31.5% (p < 0.0001) in the untreated group. Mortality (from any cause) was significantly lower in men treated with statins (p = 0.0148).</p><p><strong>Conclusion: </strong>The prediction of cardiovascular events was better with plaque burden measurements than with the PROCAM score. Treatment with statins in subjects with advanced carotid atherosclerosis (types III-IV b findings on ultrasound) significantly improved the prognosis in a nonrandomized observational study.</p>","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"60-68"},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9754236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[ESC guidelines 2023 on the management of endocarditis : What is new?] [2023年ESC心内膜炎治疗指南:有哪些新内容?]
IF 1.7 4区 医学
Herz Pub Date : 2024-02-01 Epub Date: 2023-12-13 DOI: 10.1007/s00059-023-05225-y
Suzanne de Waha, Steffen Desch, Roland Tilz, Julia Vogler, Madlen Uhlemann, Mateo Marín-Cuartas, Matthias Raschpichler, Michael Borger
{"title":"[ESC guidelines 2023 on the management of endocarditis : What is new?]","authors":"Suzanne de Waha, Steffen Desch, Roland Tilz, Julia Vogler, Madlen Uhlemann, Mateo Marín-Cuartas, Matthias Raschpichler, Michael Borger","doi":"10.1007/s00059-023-05225-y","DOIUrl":"10.1007/s00059-023-05225-y","url":null,"abstract":"<p><p>In August 2023 the new European guidelines on the management of infective endocarditis were published by the European Society of Cardiology (ESC). Numerous recommendations were revised and supplemented by new ones. This review article outlines the essential modifications of the current ESC guidelines focusing on the prevention including antibiotic prophylaxis, the role of the endocarditis team, the revision of the diagnostic criteria, the paradigm shift towards oral antibiotic treatment, the timing and the indications for surgical treatment as well as the relevance of infections of cardiovascular implantable electronic devices.</p>","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"33-42"},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138802891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Management of cardiovascular diseases in patients with diabetes : ESC guidelines 2023]. 糖尿病患者心血管疾病的管理:ESC指南2023。
IF 1.7 4区 医学
Herz Pub Date : 2024-02-01 Epub Date: 2023-10-25 DOI: 10.1007/s00059-023-05218-x
Nikolaus Marx, Dirk Müller-Wieland, Marlo Verket, Katharina Schütt
{"title":"[Management of cardiovascular diseases in patients with diabetes : ESC guidelines 2023].","authors":"Nikolaus Marx, Dirk Müller-Wieland, Marlo Verket, Katharina Schütt","doi":"10.1007/s00059-023-05218-x","DOIUrl":"10.1007/s00059-023-05218-x","url":null,"abstract":"<p><p>Patients with diabetes mellitus have an increased risk for the development of cardiovascular diseases. The presence of both comorbidities has a major impact not only on the prognosis of the patients but is also decisive for the implementation of evidence-based treatment strategies for reduction of the cardiovascular risk. The new guidelines of the European Society of Cardiology (ESC) were published in 2023 and provide clear recommendations for the management of cardiovascular diseases in patients with diabetes. The most relevant aspects of these guidelines are summarized in the following overview article.</p>","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"15-18"},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50157687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Management of acute coronary syndrome : ESC guidelines 2023]. [急性冠脉综合征的治疗:ESC指南2023]。
IF 1.7 4区 医学
Herz Pub Date : 2024-02-01 Epub Date: 2023-11-30 DOI: 10.1007/s00059-023-05222-1
Maria Buske, Hans-Josef Feistritzer, Alexander Jobs, Holger Thiele
{"title":"[Management of acute coronary syndrome : ESC guidelines 2023].","authors":"Maria Buske, Hans-Josef Feistritzer, Alexander Jobs, Holger Thiele","doi":"10.1007/s00059-023-05222-1","DOIUrl":"10.1007/s00059-023-05222-1","url":null,"abstract":"<p><p>The new guidelines of the European Society of Cardiology (ESC) on the management of acute coronary syndrome (ACS) in 2023 encompass updates for both the guidelines pertaining to ST elevation myocardial infarction (STEMI) and acute coronary syndrome without ST segment elevation (NSTE-ACS). The previously separated guidelines from 2017 and 2020 were therefore revised and summarized. These guidelines address various topics, including diagnostics, acute management, antithrombotic treatment, out-of-hospital cardiac arrest, cardiogenic shock, invasive strategies, and long-term treatment. The notable updates compared to earlier guidelines address the recommendation regarding the timing of invasive diagnostics in NSTE-ACS (Non-ST elevation acute coronary syndrome), the procedure of revascularization in multivessel coronary artery disease and alternative regimens for antithrombotic treatment in patients with a high risk of bleeding.</p>","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"5-14"},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138459490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[New 2023 guidelines: many recommendations, but few surprises]. [新的 2023 年指导方针:建议很多,但惊喜很少]。
IF 1.7 4区 医学
Herz Pub Date : 2024-02-01 Epub Date: 2024-01-31 DOI: 10.1007/s00059-023-05227-w
Bernhard Maisch, Rolf Dörr
{"title":"[New 2023 guidelines: many recommendations, but few surprises].","authors":"Bernhard Maisch, Rolf Dörr","doi":"10.1007/s00059-023-05227-w","DOIUrl":"10.1007/s00059-023-05227-w","url":null,"abstract":"","PeriodicalId":12863,"journal":{"name":"Herz","volume":"49 1","pages":"1-4"},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139650664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is lysosomal acid lipase activity associated with the presence and severity of coronary artery disease? 溶酶体酸性脂肪酶活性与冠心病的存在和严重程度有关吗?
IF 1.7 4区 医学
Herz Pub Date : 2024-02-01 Epub Date: 2023-08-01 DOI: 10.1007/s00059-023-05200-7
Emrullah Kızıltunç, Sabire Gökalp, Gürsel Biberoğlu, Yakup Yalçın, Burcu Cihan, Rıdvan M Öktem, Aslı İnci, Leyla Tümer, Mehmet R Yalçın, Adnan Abacı
{"title":"Is lysosomal acid lipase activity associated with the presence and severity of coronary artery disease?","authors":"Emrullah Kızıltunç, Sabire Gökalp, Gürsel Biberoğlu, Yakup Yalçın, Burcu Cihan, Rıdvan M Öktem, Aslı İnci, Leyla Tümer, Mehmet R Yalçın, Adnan Abacı","doi":"10.1007/s00059-023-05200-7","DOIUrl":"10.1007/s00059-023-05200-7","url":null,"abstract":"<p><strong>Background: </strong>Lipid metabolism is considerably complex and there can be many critical steps in atherogenesis. The association between lysosomal acid lipase (LAL) activity and coronary artery disease (CAD) has not been elucidated in detail. We aimed to evaluate the association between LAL activity with the presence and severity of CAD in patients who are seen in daily clinical practice.</p><p><strong>Methods: </strong>Patients who underwent coronary angiography were divided into groups according to the angiography results. Syntax scores and Gensini scores were calculated. The LAL activity was measured from dried blood spots.</p><p><strong>Results: </strong>Median LAL activity values were similar in all study groups (normal coronary arteries: 0.40 nmol/punch/h; non-obstructive CAD: 0.44 nmol/punch/h; obstructive chronic CAD: 0.40 nmol/punch/h; obstructive acute coronary syndrome: 0.48 nmol/punch/h) and there was no correlation between coronary atherosclerotic burden and LAL activity (correlation coefficients Syntax score and LAL: -0.032; Gensini score and LAL: -0.030). In addition, no relationship between serum lipid levels and LAL activity was detected.</p><p><strong>Conclusion: </strong>The presence of CAD and its severity is not associated with the LAL activity in patients encountered in daily clinical practice.</p>","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"75-80"},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10277677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accuracy of VO2 estimation according to the widely used Krakau formula for the prediction of cardiac output. 根据广泛使用的克拉考公式预测心输出量的 VO2 估计值的准确性。
IF 1.1 4区 医学
Herz Pub Date : 2024-02-01 Epub Date: 2023-07-13 DOI: 10.1007/s00059-023-05196-0
Theresa Reiter, Julia Kerzner, Georg Fette, Stefan Frantz, Wolfram Voelker, Georg Ertl, Wolfgang Bauer, Caroline Morbach, Stefan Störk, Gülmisal Güder
{"title":"Accuracy of VO<sub>2</sub> estimation according to the widely used Krakau formula for the prediction of cardiac output.","authors":"Theresa Reiter, Julia Kerzner, Georg Fette, Stefan Frantz, Wolfram Voelker, Georg Ertl, Wolfgang Bauer, Caroline Morbach, Stefan Störk, Gülmisal Güder","doi":"10.1007/s00059-023-05196-0","DOIUrl":"10.1007/s00059-023-05196-0","url":null,"abstract":"<p><strong>Background: </strong>Invasive cardiac output (CO) is measured with the thermodilution (TD) or the indirect Fick method (iFM) in right heart catheterization (RHC). The iFM estimates CO using approximation formulas for oxygen consumption ([Formula: see text]O<sub>2</sub>), but there are significant discrepancies (> 20%) between both methods. Although regularly applied, the formula proposed by Krakau has not been validated. We compared the CO discrepancies between the Krakau formula with the reference (TD) and three established formulas and investigated whether alterations assessed in cardiac magnetic resonance imaging (CMR) determined the extent of the deviations.</p><p><strong>Methods: </strong>This retrospective study included 188 patients aged 63 ± 14 years (30% women) receiving both CMR and RHC. The CO was measured with TD or with the iFM using the formulas by Krakau, LaFarge, Dehmer, and Bergstra for [Formula: see text]O2 estimation (iFM-K/-L/-D/-B). Percentage errors were calculated as twice the standard deviation of the difference between two CO methods divided by their means; a cut-off of < 30% was regarded as acceptable. The iFM and TD-derived CO ratio was built, and deviations > 20% were counted. Logistic regression analyses were performed to identify determinants of a deviation of > 20%.</p><p><strong>Results: </strong>The TD-derived CO (5.5 ± 1.7 L/min) was significantly different from all iFM (K: 4.8 ± 1.6, L: 4.3 ± 1.6; D: 4.8 ± 1.5 L/min; B: 5.4 ± 1.8 L/min all p < 0.05). The iFM-K-CO differed from all methods (p < 0.001) except iFM‑D (p = 0.19). Percentage errors between TD-CO and iFM-K/-L/-D/-B were all beyond the acceptance limit (44/45/44/43%), while percentage errors between iFM‑K and other iFM were all < 16%. None of the parameters measured in CMR was predictive of a discrepancy of > 20% between both methods.</p><p><strong>Conclusion: </strong>The Krakau formula was comparable to other iFM in estimating CO levels, but none showed satisfactory agreement with the TD method. Improved derivation cohorts for [Formula: see text]O<sub>2</sub> estimation are needed that better reflect today's patients undergoing RHC.</p>","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"50-59"},"PeriodicalIF":1.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10830659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9773478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信